CanSino Biologics Launches Phase I/II Clinical Trials for Recombinant Polio Vaccine
December 25, 2024
Source: drugdu
33
Finance China News, December 20 – CanSino Biologics (688185/06185) released a voluntary disclosure announcing that its developed recombinant polio vaccine has initiated Phase I/II clinical trials in Indonesia, with the first subject enrolled in phase I. This vaccine utilizes virus-like particle technology, making it non-infectious, and is expected to perform well in terms of safety and immunogenicity. It is considered one of the preferred vaccines for the future eradication of polio, as recommended by the World Health Organization.
This clinical trial will further assess the vaccination safety and immunogenicity of the vaccine in specific age groups of infants and young children. The announcement highlighted the complexity and uncertainty of vaccine development, stressing the unpredictability of the clinical trial process and results, advising investors to make cautious decisions.
In the first three quarters of 2024, CanSino achieved revenue of 567 million yuan, with a net profit attributable to the parent company of -222 million yuan.
https://finance.eastmoney.com/a/202412203274627079.html
By editor
Copyright©2024 Ddu. All rights reserved.
Read more on
- Chuangxiang Biotechnology and Ikena Oncology merge to raise $75 million in funding December 25, 2024
- Two biosimilars of pembrolizumab have been approved for marketing, and the second indication of Cononospikinumab has been approved December 25, 2024
- ABB’s maintenance plan based on equipment status helps Jiheng Pharmaceutical December 25, 2024
- CR Group’s Big Move – Integration of Two Major Pharmaceutical Companies Completed December 25, 2024
- Zhongshan Pharmaceutical’s “Class 1.1 Chinese Medicine for Gastric Diseases” has been approved for listing December 25, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
